Birmingham, United Kingdom

The Binding Site Group

www.bindingsite.co.uk
Birmingham, United Kingdom
SEARCH FILTERS
Time filter
Source Type

Patent
University of Warwick and The Binding Site Group | Date: 2013-02-15

The invention provides a method of estimating free light chain production (FLC) in a subject comprising (i) determining an amount of FLC in a sample from the subject; and (ii) correcting the amount of FLC in the sample for FLC cleared from the source of the sample by glomerular filtration and by reticuloendothelial (RE) clearance.


Jenner E.,The Binding Site Group
Clinica Chimica Acta | Year: 2014

Monoclonal free light chains (FLCs) are important disease biomarkers in patients with plasma cell-proliferative disorders. The increasing evidence for clonal diversity and evolution in multiple myeloma highlights the importance of laboratory algorithms that measure both intact immunoglobulins and monoclonal FLCs, at diagnosis and when monitoring response to treatment. A particular focus in the field has been on the utility of serum FLC (sFLC) assays to replace urine electrophoresis for monoclonal FLC measurement. Due to the limited sensitivity and practical constraints of urine analysis, a serum-based algorithm of SPE and sFLC has been adopted by many laboratories as a first line screen in patients with suspected monoclonal gammopathies. This review will discuss the data supporting the use of this simple serum-based algorithm at initial diagnosis, including its utility for the rapid identification of monoclonal FLC in the setting of unexplained acute kidney injury, and provide a comprehensive review of the diagnostic sensitivity of sFLC in patients with multiple myeloma, AL amyloidosis and light chain deposition disease. © 2013 The Authors.


Patent
The Binding Site Group | Date: 2011-10-26

The invention relates to a method of coating beads with a biological molecule comprising: (i) coating a plurality of beads with the biological molecule; (ii) mixing the coated beads with a liquid stabilising and/or blocking agent (iii) dispersing the coated beads still substantially surrounded by a liquid phase comprising the liquid stabilising and/or blocking agent across a surface that is at least partially liquid permeable; (iv) drying the beads on the surface to substantially remove the liquid phase; and (v) removing the dried beads from the surface.


Patent
The Binding Site Group | Date: 2011-02-04

The invention provides a method of prognosis of a subject with a cancer, identifying a subject having a greater risk of having an undiagnosed cancer and/or identifying a subject at greater risk of developing a cancer the method comprising detecting an amount of free light chains (FLC) in a sample from a subject, wherein a higher amount of FLC is associated with decreased survival due to a cancer and/or increased risk of the subject having an undiagnosed cancer and/or having an increased risk of developing a cancer.


Patent
The Binding Site Group | Date: 2014-11-05

The invention provides an assay kit for the determination of the total amount of free light chains (FLC) in a serum, whole blood or plasma sample comprising two or more detection agents to detect the total amount of FLC in a sample, the one or more detection agents comprising polyclonal anti-free antibodies or fragments thereof and polyclonal anti-free antibodies or fragments thereof, wherein the antibodies or fragments are mixed together. The invention also provides an assay kit for the determination of the total amount of free light chains (FLC) in a sample comprising two or more detection agents to detect the total amount of FLC in a sample, wherein the assay kit is an ELISA, a flow cytometry kit comprising different size beads, a nephelometric or turbidimetric kit.


Patent
The Binding Site Group | Date: 2013-03-06

The invention provides a method for characterising a plasma cell associated disease in a patient comprising: (i) providing at least one sample from the patient; (ii) determining in the sample(s) two or more of; (a) the : free light chain (FLC) ratio; (b) the ratio of light chains bound to a class of heavy chain: light chain bound to the same class of heavy chain (HLC:HLC ratio); (c) the total amount of FLC in the samples and (d) the total amount of light chains bound to the heavy chain class plus light chains bound to the same heavy chain class (total HLC); (iii) comparing each ratio or amount from (a) (b), (c) and/or (d) to predetermined values and assigning a score to each amount or ratio; and (iv) using the scores to characterise the plasma cell associated disease. Apparatus configured to carry out the method of the invention are also provided. The invention also provides a kit comprising, in combination, (i) anti- FLC specific and anti- FLC specific antibodies or fragments thereof and (ii) anti- heavy chain class specific and anti- heavy chain class specific antibodies or fragments thereof, optionally mixed together.


Patent
The Binding Site Group | Date: 2011-01-21

A method of detecting or monitoring a malignant plasma cell disease comprising detecting in a sample the ratio between the relative amounts of immunoglobulins having:


Patent
The Binding Site Group | Date: 2011-03-03

The invention provides a method of predicting subjects at risk of loss of kidney function and/or identifying subjects at greater risk of loss of kidney function, and/or identifying subjects at risk of kidney failure/end stage kidney disease, the method comprising detecting an amount of free light chains (FLC) in a sample from the subject, wherein a higher amount of FLC is associated with increased risk of loss of kidney function and/or increased risk of renal failure/end stage kidney disease. A further aspect of the invention provides a method of monitoring renal impairment, comprising detecting an amount of free light chains (FLC) in a sample from a subject having renal impairment and comparing the amount of FLC in the sample with an Total FLC amount of FLC detected in a sample previously obtained from the subject, wherein an increase in the amount FLC detected, compared to the previous sample, indicates an increase in the risk of loss of renal function in the subject, and a decrease in the amount of FLC indicates a decrease in the risk of loss of renal function in the subject.


Patent
The Binding Site Group | Date: 2011-06-02

The invention provides a method detecting free light chains (FLCs) comprising: (i)providing a sample from a subject; (ii)mixing the sample with an anti-FLC specific antibody, or fragments thereof capable of specifically binding the FLC, to form a mixture; (iii)passing the mixture through a capillary tube by capillary zone electrophoresis (CZE); and (iv)detecting the presence of the antibody or fragment thereof after passage through at least a portion of the capillary tube. Capillary tubes for use in CZE and kits comprising capilliary tubes and at least one anti-FLC antibody are also provided.


Patent
The Binding Site Group | Date: 2013-07-10

The application discloses a method of determining the severity of symptoms in a patient comprising (i) producing a triage score, such as an early warning score (EWS) modified early warning score (MEWS), paediatric early warning score (PEWS), NHS early warning score (NEWS), simple clinical score (SCS), rapid emergency score (REMS) or mortality in emergency department sepsis score for the patient, (ii) measuring an amount of free light chains (FLC), preferably combined free light chains (cFLC), in a sample from the patient, and (iii) using the triage score and the amount of FLC measured to assess the severity of symptoms in the patient. This also allows patients to be triaged to provide better treatment of them.

Loading The Binding Site Group collaborators
Loading The Binding Site Group collaborators